In which cases would you use adjuvant abemaciclib for a patient with extensive residual disease that is triple-positive (ER+PR+HER2+) following neoadjuvant TCHP?

Would you consider adjuvant abemaciclib in a patient with ER+PR+HER2+ residual disease after neoadjuvant TCHP?

• No, would use TDM-1 alone
• Yes, adjuvant abemaciclib and no further HER2-target therapy
• Yes, adjuvant abemaciclib after trastuzumab +/- pertuzumab
• Yes, adjuvant abemaciclib after TDM-1
• Other